Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Viganò L, Gatti A, Minoia C, Liati P, Van den Bosch S, Bernareggi A, Camboni G, Marsoni S. Sessa C, et al. Among authors: bernareggi a. Ann Oncol. 2000 Aug;11(8):977-83. doi: 10.1023/a:1008302309734. Ann Oncol. 2000. PMID: 11038034 Free article. Clinical Trial.
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, Bernareggi A. Mross K, et al. Among authors: bernareggi a. Anticancer Drugs. 2004 Jan;15(1):15-22. doi: 10.1097/00001813-200401000-00003. Anticancer Drugs. 2004. PMID: 15090738 Clinical Trial.
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G, Chilingirova N, Rizzi G, Caccia T, Stella V, Bernareggi A. Kurteva G, et al. Among authors: bernareggi a. Eur J Pharm Sci. 2019 Nov 1;139:105041. doi: 10.1016/j.ejps.2019.105041. Epub 2019 Aug 9. Eur J Pharm Sci. 2019. PMID: 31404621 Clinical Trial.
81 results